58096-02-9

Upstream product

• 3249-68-1 ethyl butyroyl acetate 
• 927-77-5 n-propylmagnesium bromide 
• 105-56-6 ethyl 2-cyanoacetate 
• 64-17-5 ethanol 
• 77570-19-5 5-(1-Amino-butylidene)-2,2-dimethyl-[1,3]dioxane-4,6-dione 

Downstream Products

• 1027941-26-9 3-[2'-(4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-biphenyl-4-ylmethyl]-4-methyl-2-propyl-pyridine 
• 1028263-80-0 [2'-(4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-biphenyl-4-yl]-(4-methyl-2-propyl-pyridin-3-yl)-methanol 
• 1025930-26-0 3-{Chloro-[2'-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-biphenyl-4-yl]-methyl}-4-methyl-2-propyl-pyridine 
• 150190-13-9 5-Ethoxycarbonyl-3-methoxycarbonyl-2-oxo-4-phenyl-6-propyl-1,2,3,4-tetrahydropyridine 
• 1116572-42-9 ethyl 6-methyl-2-propylpyridine-3-carboxylate 

Relevant academic research and scientific papers

Synthesis of β-amino acid derivatives via copper-catalyzed asymmetric 1,4-reduction of β-(acylamino)acrylates

A new set of reaction conditions has been established to facilitate the copper-catalyzed enantioselective 1,4-reduction of β-(acylamino)acrylates toward a selection of β-alkyl-β-amino acid derivatives in high yields and with uniformly high ee values (up to 99%) irrespective of the use of (E)- or (Z)-substrates.

C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin

Materials and methods for preparing (S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid and structurally related compounds via enantioselective hydrogenation of prochiral olefins are disclosed. The methods employ novel chiral catalysts, which include C1-symmetric bisphosphine ligands bound to transition metals.

Benzoxazines for use in the treatment of parkinson's disease

Benzoxazines of Formula (I) wherein R1 is C1-C6 alkyl, C2-C6 alkenyl, or (CH2)n phenyl, R2 is C3-C6 alkyl, R3 is hydrogen, halo, hydro